Management of Sexually Inappropriate Behavior in Dementia
Begin with a systematic non-pharmacological approach using the DICE framework (Describe, Investigate, Create, Evaluate) before considering any medication changes, as this is the recommended first-line strategy for neuropsychiatric symptoms in dementia 1, 2.
Immediate Assessment Steps
1. Describe and Investigate the Behavior
- Document the specific type, frequency, severity, pattern, and timing of the sexually inappropriate behaviors 2
- Assess for modifiable contributors:
- Pain or physical discomfort (urinary tract infection, constipation, skin irritation in genital area)
- Medication side effects - particularly concerning in this patient:
- Depakote (valproate) causes significant somnolence in elderly dementia patients and should be evaluated for dose reduction or discontinuation 3
- Olanzapine (Zyprexa) can cause disinhibition paradoxically
- Delirium (check for acute medical illness, infection)
- Environmental triggers (overstimulation, lack of privacy, misinterpretation of care activities)
- Unmet needs (boredom, loneliness, need for intimacy/touch)
2. Critical Medication Review
Consider discontinuing or reducing Depakote - The FDA label specifically warns that valproate in elderly dementia patients (mean age 83, matching this patient) causes significantly higher somnolence, dehydration, reduced nutritional intake, and weight loss 3. The current dose of 125 mg BID is low but may still contribute to behavioral changes. Valproate has no proven efficacy for behavioral symptoms in dementia and carries substantial risks in this population.
Non-Pharmacological Interventions (First-Line)
Implement These Strategies:
- Distraction/redirection when inappropriate behaviors occur - most commonly effective intervention 4
- Structured daily routine with meaningful activities tailored to patient's interests and abilities 1
- Environmental modifications:
- Ensure adequate privacy
- Reduce overstimulation
- Simplify surroundings
- Caregiver education:
- Behaviors are not intentional but symptoms of brain disease
- Use calm tones, simple single-step commands
- Avoid confrontation or negative reactions
- Provide appropriate physical touch (hand-holding, shoulder pat) to meet need for human contact 1
Monitor for 2-4 Weeks
Evaluate whether strategies were implemented and effective before considering pharmacological intervention 1, 2.
Pharmacological Management (If Non-Pharmacological Fails)
Antidepressants (SSRIs) are first-line pharmacological treatment for sexually inappropriate behaviors in dementia when non-pharmacological approaches fail 4, 5, 6, 7.
Recommended Approach:
Step 1: Start SSRI
- Citalopram 10 mg daily or Sertraline 25 mg daily 5, 6, 7
- Titrate slowly over 4-6 weeks to effect
- Maximum citalopram dose: 20 mg daily in elderly (QTc prolongation risk)
- Monitor for hyponatremia, falls, GI bleeding (especially with concurrent aspirin)
Step 2: If SSRI Ineffective After 4-Week Trial
- Consider antiandrogen therapy (second-line) 7:
- Medroxyprogesterone acetate 100-400 mg weekly IM
- Requires medical clearance (cardiovascular risk assessment)
- More appropriate for severe, dangerous behaviors
Step 3: Third-Line Options (for refractory cases)
- LHRH agonists (leuprolide) - requires specialist consultation 7
- Consider increasing Aricept to 10 mg daily (cholinesterase inhibitors may help with disinhibition) 8
What NOT to Do:
- Do not increase Zyprexa - antipsychotics show modest efficacy for disinhibition and carry significant mortality risk in dementia 1, 2
- Do not add mood stabilizers - patient already on Depakote with questionable benefit
- Avoid benzodiazepines - increase confusion and disinhibition
Critical Safety Considerations
Black Box Warnings:
- Antipsychotics increase mortality in elderly dementia patients - use only for severe aggression/psychosis causing imminent danger 2
- Current Zyprexa 5 mg should be evaluated for necessity and considered for taper if not addressing specific dangerous behaviors
Follow-Up Protocol:
- Reassess at 2 weeks, then 4 weeks after any intervention
- Use quantitative measure to track behavior frequency/severity 2
- If medication started and effective, attempt taper after 3-6 months of stability 2
- Monitor for adverse effects: somnolence, falls, hyponatremia, QTc prolongation
Ethical Considerations
Discuss with family/surrogate decision-maker 2:
- Goals of treatment (safety vs. quality of life)
- Risks and benefits of pharmacological intervention
- Patient's prior values and preferences regarding sexuality
- Distinction between inappropriate behavior vs. appropriate expression of sexuality in wrong context
Common Pitfall: Treating all sexual behavior as pathological - some behaviors may represent appropriate needs expressed inappropriately due to cognitive impairment. The goal is redirection, not complete suppression of normal human needs.